跳至主要内容
临床试验/DRKS00016731
DRKS00016731已完成不适用

Predictive value of ultrasonographic parameters fortherapy response in Crohn’s disease and ulcerativecolitis patients - TRUST BEYOND

AbbVie Deutschland GmbH & Co. KG0 个研究点目标入组 246 人开始时间: 2019年5月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
246

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Written informed consent
  • - Patients = 18 years
  • - CD: Patients with a proven diagnosis of Crohn’s disease or ulcerative colitis, and moderate to severe disease activity who have been selected for start of TIM therapy.
  • - Patients with increased bowel wall thickness (BWT) at baseline

排除标准

  • - Patients post bowel resection surgery, patients with ileal stoma or ileoanal pouch
  • - CD patients with disease restricted to small bowel other than terminal ileum, gastroduodenal or anorectal areas
  • - UC patients having disease limited to the rectum (ulcerative proctitis)
  • - Patients with therapy failure to more than 2 prior biologics/JAK-therapy
  • - Patients who cannot be examined by ultrasound
  • - Pregnant at study start
  • - Infectious colitis (e.g. Cytomegalovirus (CMV), Clostridium Difficile (C.diff)
  • - Preparation of endoscopy at day of Gastrointestinal Ultrasound (GIUS) assessment or on the day before

研究者

相似试验